Ranbaxy
•Download as PPTX, PDF•
0 likes•286 views
USA, Europe and India are Ranbaxy's three largest markets. The Indian pharmaceutical market grew nearly 17% in 2009 to Rs. 401 billion and is projected to become one of the top 10 markets globally, reaching $20 billion by 2015 and $30 billion by 2020 with 11-12% annual growth. In 2009, Ranbaxy recorded global sales of $1.519 billion while setting up a new manufacturing facility in South Africa.
Report
Share
Report
Share
Recommended
Ch01
1. The document discusses the evolution of global marketing from early domestic and export stages to the current stage of global marketing where companies adopt a global perspective and develop global products with local variations.
2. It describes the five stages in the evolution: domestic marketing, export marketing, international marketing, multinational marketing, and global marketing. Global marketing involves standardization, coordination across markets, and global integration.
3. The document emphasizes that global marketing does not mean products can be developed anywhere as economic, climate, and cultural factors still affect development. The internet adds a new dimension by enabling cost savings through e-commerce.
Fertilizer global market report 2018 sample
The global fertilizer market was valued at $357 billion in 2017.
Read more:https://www.thebusinessresearchcompany.com/report/fertilizer-global-market-report-2018
Global Marketing Management, 5th ed
This document provides an overview of chapter 1 from a global marketing textbook. It discusses the increasing globalization of markets and importance of global marketing. Key points covered include the convergence and divergence of global consumer behavior, the evolution of global marketing strategies from domestic to international to global, and theories of international trade such as comparative advantage and the international product life cycle.
Partnering With A CMO In China
Many biopharmaceutical companies are considering partnering with contract manufacturing organizations (CMOs) in China to take advantage of lower costs and access to the growing Chinese market. However, companies must carefully consider key cultural issues when selecting a CMO in China. China's pharmaceutical industry is large and growing rapidly as the country shifts to higher value products. While most Chinese drug exports are active pharmaceutical ingredients, finished drug products will likely enter other markets as well. Partnering with a CMO could provide biotech companies an entry into China, but they must also consider how much biotech may share in the general expansion given its short history in China. Cultural due diligence is important when selecting a Chinese CMO partner.
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
Pharma industry 1-4_9_29_50
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Aurobindo Pharma - Initiating coverage - Natverlal Research
- Aurobindo Pharma is an Indian pharmaceutical company with a global presence in generic drug manufacturing.
- Its US business is a major growth driver, contributing 45% of sales, and it expects to launch 30-40 new products in the US in FY2017.
- It acquired Actavis' European operations in FY2015, turning around its European business which is now its second largest market.
- The company is entering more complex drug areas like peptides and controlled substances which have limited competition.
indian pharmaceutical industry
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Recommended
Ch01
1. The document discusses the evolution of global marketing from early domestic and export stages to the current stage of global marketing where companies adopt a global perspective and develop global products with local variations.
2. It describes the five stages in the evolution: domestic marketing, export marketing, international marketing, multinational marketing, and global marketing. Global marketing involves standardization, coordination across markets, and global integration.
3. The document emphasizes that global marketing does not mean products can be developed anywhere as economic, climate, and cultural factors still affect development. The internet adds a new dimension by enabling cost savings through e-commerce.
Fertilizer global market report 2018 sample
The global fertilizer market was valued at $357 billion in 2017.
Read more:https://www.thebusinessresearchcompany.com/report/fertilizer-global-market-report-2018
Global Marketing Management, 5th ed
This document provides an overview of chapter 1 from a global marketing textbook. It discusses the increasing globalization of markets and importance of global marketing. Key points covered include the convergence and divergence of global consumer behavior, the evolution of global marketing strategies from domestic to international to global, and theories of international trade such as comparative advantage and the international product life cycle.
Partnering With A CMO In China
Many biopharmaceutical companies are considering partnering with contract manufacturing organizations (CMOs) in China to take advantage of lower costs and access to the growing Chinese market. However, companies must carefully consider key cultural issues when selecting a CMO in China. China's pharmaceutical industry is large and growing rapidly as the country shifts to higher value products. While most Chinese drug exports are active pharmaceutical ingredients, finished drug products will likely enter other markets as well. Partnering with a CMO could provide biotech companies an entry into China, but they must also consider how much biotech may share in the general expansion given its short history in China. Cultural due diligence is important when selecting a Chinese CMO partner.
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
Pharma industry 1-4_9_29_50
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Aurobindo Pharma - Initiating coverage - Natverlal Research
- Aurobindo Pharma is an Indian pharmaceutical company with a global presence in generic drug manufacturing.
- Its US business is a major growth driver, contributing 45% of sales, and it expects to launch 30-40 new products in the US in FY2017.
- It acquired Actavis' European operations in FY2015, turning around its European business which is now its second largest market.
- The company is entering more complex drug areas like peptides and controlled substances which have limited competition.
indian pharmaceutical industry
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Pharma Industry
1. The global pharmaceutical market reached $942 billion in 2011 and is expected to reach $1.12 trillion by 2022 due to population growth and an aging population.
2. The Indian pharmaceutical market is estimated to reach $55 billion by 2020, growing faster than the global market, and will be dominated by drugs for non-communicable diseases.
3. The growth of the pharmaceutical industry in both global and Indian markets is driven by increasing healthcare spending, rising incomes, and a shift toward specialty and chronic disease drugs.
Stock of the week sunpharma
STOCK OF THE WEEK - SUNPHARMA LTD.
● Company Profile
● Key Highlightes
● Organisation Performance
● Investment Rational
● Q1 FY 2020 Highlights
● Financial Performance
Ranbaxy
Ranbaxy is India's largest pharmaceutical company with a global presence in 43 countries. It produces generic medicines and has world-class manufacturing facilities. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse. The Indian pharmaceutical industry is the 3rd largest globally by volume and Ranbaxy is a leading player in this industry.
India : Pharmaceuticals Sector Report_August 2013
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
Overview of the Pharma industry
The Indian pharmaceutical industry has grown tremendously over the past few decades from being almost non-existent to meeting nearly 95% of the country's pharmaceutical needs. It is now self-reliant in terms of production capabilities across a wide range of medicines. The industry is highly fragmented with over 20,000 registered units and is characterized by intense price competition and government price controls. Exports have also increased significantly and are expected to surpass domestic sales in the coming years, driven primarily by growth in formulation exports. India also has the most FDA-approved manufacturing facilities outside of the US, positioning it as an important supplier for the global pharmaceutical market.
Pharmaceuticals Sector Report March 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Pharmaceuticals Sector Report - March 2019
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
Pharmaceuticals Sector Report - February 2019
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
Pharmaceuticals Sector Report - April 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
Pharmaceuticals Sector Report - February 2018
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
Pharmaceuticals July-2019
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
Financial Management in Pharmaceutical industry
The report was prepared with the overview of global pharmaceutical markets and Asian markets with special emphasis on emerging markets such as India.
Indian Pharmaceutical Market Overview 2013 by Nitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Pharmaceuticals Sector Report - January 2019
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Pharmaceuticals Sector Report - April 2019
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
Pharmaceuticals Sector Report - December 2018
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Pharmaceutical industry in india
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.
Indian Pharma Market Overview -2018
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
Pharmaceuticals Sector Report - January 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
Bio10PharmaIndiaInternational
Bio10 Pharma is a licensed pharmaceutical distributor based in Guwahati, India. The company's objective is to market and supply pharmaceutical products and services to hospitals, government institutions, healthcare professionals, and retailers. Its goals include creating a widespread supply network, establishing long-term client relationships, maintaining quality, and improving accessibility of medicines in remote areas. The company offers a wide range of medical supplies and drugs, dealing with premium brands. It aims to contribute to improving public health in the region through its work.
More Related Content
Similar to Ranbaxy
Pharma Industry
1. The global pharmaceutical market reached $942 billion in 2011 and is expected to reach $1.12 trillion by 2022 due to population growth and an aging population.
2. The Indian pharmaceutical market is estimated to reach $55 billion by 2020, growing faster than the global market, and will be dominated by drugs for non-communicable diseases.
3. The growth of the pharmaceutical industry in both global and Indian markets is driven by increasing healthcare spending, rising incomes, and a shift toward specialty and chronic disease drugs.
Stock of the week sunpharma
STOCK OF THE WEEK - SUNPHARMA LTD.
● Company Profile
● Key Highlightes
● Organisation Performance
● Investment Rational
● Q1 FY 2020 Highlights
● Financial Performance
Ranbaxy
Ranbaxy is India's largest pharmaceutical company with a global presence in 43 countries. It produces generic medicines and has world-class manufacturing facilities. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse. The Indian pharmaceutical industry is the 3rd largest globally by volume and Ranbaxy is a leading player in this industry.
India : Pharmaceuticals Sector Report_August 2013
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
Overview of the Pharma industry
The Indian pharmaceutical industry has grown tremendously over the past few decades from being almost non-existent to meeting nearly 95% of the country's pharmaceutical needs. It is now self-reliant in terms of production capabilities across a wide range of medicines. The industry is highly fragmented with over 20,000 registered units and is characterized by intense price competition and government price controls. Exports have also increased significantly and are expected to surpass domestic sales in the coming years, driven primarily by growth in formulation exports. India also has the most FDA-approved manufacturing facilities outside of the US, positioning it as an important supplier for the global pharmaceutical market.
Pharmaceuticals Sector Report March 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Pharmaceuticals Sector Report - March 2019
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
Pharmaceuticals Sector Report - February 2019
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
Pharmaceuticals Sector Report - April 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
Pharmaceuticals Sector Report - February 2018
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
Pharmaceuticals July-2019
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
Financial Management in Pharmaceutical industry
The report was prepared with the overview of global pharmaceutical markets and Asian markets with special emphasis on emerging markets such as India.
Indian Pharmaceutical Market Overview 2013 by Nitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Pharmaceuticals Sector Report - January 2019
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Pharmaceuticals Sector Report - April 2019
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
Pharmaceuticals Sector Report - December 2018
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Pharmaceutical industry in india
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.
Indian Pharma Market Overview -2018
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
Pharmaceuticals Sector Report - January 2018
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
Bio10PharmaIndiaInternational
Bio10 Pharma is a licensed pharmaceutical distributor based in Guwahati, India. The company's objective is to market and supply pharmaceutical products and services to hospitals, government institutions, healthcare professionals, and retailers. Its goals include creating a widespread supply network, establishing long-term client relationships, maintaining quality, and improving accessibility of medicines in remote areas. The company offers a wide range of medical supplies and drugs, dealing with premium brands. It aims to contribute to improving public health in the region through its work.
Similar to Ranbaxy (20)
Indian Pharmaceutical Market Overview 2013 by Nitesh Bhele
Indian Pharmaceutical Market Overview 2013 by Nitesh Bhele
Ranbaxy
- 7. The Indian pharmaceutical market grew at a robust 16.9% in 2009 to Rs. 401 Bn (ORG IMS MAT Dec 2009)
- 8. The Indian pharmaceutical market is expected to grow at 11-12% per annum to reach US$ 20 Bn by 2015 and US$ 30Bn by 2020, which will place it among the world's 10 largest pharmaceutical markets.
- 9. Ranbaxy recorded global consolidated sales of US$ 1,519 Mn in 2009
- 10. india sales were at Rs. 4,487 Mn (USD 98 Mn), almost at the same level as previous corresponding quarter. Excluding tenders, sales grew by 11% during the same period. For H1’10, sales were at Rs. 8,375 Mn (USD 183 Mn). Continuing its healthy performance, the Consumer Healthcare business recorded a growth of 24% during H1’10 and attained No. 1 rank in its represented market during the Quarter.